| Not Yet Recruiting | A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Partici Melanoma | Phase 1 | 2026-06-19 |
| Not Yet Recruiting | Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edem Diabetic Macular Edema | Phase 3 | 2026-03-01 |
| Completed | Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and E Healthy Male and Female Subjects | Phase 1 | 2025-02-11 |
| Terminated | Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio Ulcerative Colitis | Phase 3 | 2024-09-23 |
| Completed | Pilot Study of AVT16 in Healthy Adult Subjects Healthy | Phase 1 | 2024-05-29 |
| Completed | Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular Diseas Chorioretinal Vascular Disease | Phase 3 | 2024-02-28 |
| Completed | AVT03 With Xgeva in Healthy Male Subjects This is a Phase I Study Conducted in Healthy Volunteers | Phase 1 | 2023-07-21 |
| Completed | Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX Rheumatoid Arthritis | Phase 3 | 2023-03-30 |
| Completed | A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Par Healthy Adult Subjects | Phase 1 | 2022-12-16 |
| Completed | Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND Osteoporosis, Postmenopausal | Phase 3 | 2022-08-23 |
| Completed | AVT03 With Prolia in Healthy Male Subjects Healthy Male Subjects | Phase 1 | 2022-06-29 |
| Completed | Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) Neovascular (Wet) AMD | Phase 3 | 2022-06-28 |
| Completed | Efficacy, Safety, and Immunogenicity of AVT04 With Moderate-to-Severe Chronic Plaque Psoriasis Psoriasis | Phase 3 | 2021-06-03 |
| Completed | Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab) Psoriasis | Phase 1 | 2021-05-25 |
| Completed | Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasi Plaque Psoriasis | Phase 3 | 2020-06-30 |
| Completed | Auto-injector Real Life Handling in Patients RA | Phase 3 | 2019-11-04 |
| Completed | PK, Safety and Tolerability Study of AVT02 (Adalimumab) Pre-filled Syringe (PFS) vs, AVT02 Autoinjector (AI) Phase 1 | Phase 1 | 2019-07-01 |
| Completed | Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab) Healthy Volunteers | Phase 1 | 2019-03-20 |
| Completed | Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis Plaque Psoriasis | Phase 3 | 2019-02-20 |
| Completed | Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy V Healthy Volunteers | Phase 1 | 2018-05-21 |